Twist Posts Positive Q4 Adjusted Ebitda

The Tip Desk · November 12, 2026 · 3 min read

Fourth-quarter revenue reached $126.6 million, up 28%, as the company guided fiscal 2027 sales to $550 million to $560 million.

Twist Bioscience Corporation (TWST) reported fourth-quarter fiscal 2026 revenue of $126.6 million, a 28% increase from $99.0 million a year earlier and the 15th consecutive quarter of sequential growth.

The DNA synthesis and NGS applications company also posted adjusted EBITDA of $2.2 million, reversing a $7.8 million loss in the year-ago quarter and matching the breakeven outlook it had reiterated after the second and third quarters. Net loss narrowed to $20.6 million, or $0.32 a share, from $27.1 million, or $0.45 a share, a year earlier.

Year-over-year growth accelerated from 23% in the third quarter, when revenue was $118.4 million, and 19% in the second quarter, when it was $110.7 million. Sequential revenue rose 7% from the third quarter.

Both reportable segments contributed. DNA Synthesis and Protein Solutions revenue grew 33% to $61.0 million, up 8% sequentially from $56.6 million. NGS Applications revenue grew 24% to $65.7 million, up 6% sequentially from $61.8 million. NGS year-over-year growth had been 12% in both the second and third quarters.

Gross margin was 53.1% in the fourth quarter, up from 51.3% a year earlier. Cost of revenues was $59.4 million. Research and development expenses were $17.0 million. Selling, general and administrative expenses were $74.7 million.

For the full fiscal year ended September 30, 2026, revenue was a record $459.4 million, up 22% from $376.6 million in fiscal 2025. DSPS revenue for the year grew 31.7% to $221.9 million; NGS revenue grew 14.1% to $237.5 million. Full-year gross margin improved to 52.4% from 50.7%. Full-year net loss was $130.2 million, or $2.08 a share, compared with $77.7 million, or $1.30 a share, in fiscal 2025. Full-year adjusted EBITDA was a $35.9 million loss. The company recorded $7.2 million of litigation settlement costs, net of recoveries, in fiscal 2026.

Twist shipped products to approximately 4,100 customers in fiscal 2026, versus approximately 3,800 in fiscal 2025, and physically shipped approximately 1.3 million genes. Cash, cash equivalents and short-term investments were approximately $582 million as of September 30, 2026, after raising net proceeds of approximately $425 million through an equity offering and at-the-market sales.

Chief executive Emily M. Leproust said the company enters fiscal 2027 with capital to invest in capacity, automation and new products. For fiscal 2027, Twist expects total revenue of approximately $550 million to $560 million, about 21% year-over-year growth at the midpoint, and gross margin of approximately 52.5% to 53%. Initial full-year guidance assumes $100 million in revenue for AI drug discovery and sequential growth across both DSPS and NGS. The company also expects positive adjusted EBITDA and capital expenditures of approximately $75 million as part of a two-year investment plan, excluding landlord-funded tenant improvements.

For the first quarter of fiscal 2027, Twist expects revenue of approximately $130 million to $132 million, about 26% year-over-year growth at the midpoint, and continued sequential growth.